CETSA method formatting and kit validation
| Reference number | |
| Coordinator | Pelago Bioscience AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | June 2015 - November 2015 |
| Status | Completed |
Important results from the project
We had three milestones and work packages in the project: A) Development and validation of the CETSA method in homogenous detection formats for increased sensitivity and capacity B) Benchmarking towards existing CETSA classic assay formats C) Test of new targets and sample matrices Which, together should enable an implementation of new service formats for Pelago Bioscience based on such new detection formats
Expected long term effects
We have achieved the three milestones in the work packages and implemented the new service formats as part of our portfolio. This has been achieved in part through the establishment of a strategic collaboration with AstraZeneca and by sub licensing the CETSA method to two international pharmaceutical companies.
Approach and implementation
The project was research intensive with a very comprehensive and ambitious outline. We have during the projects adjusted and focused resources on already established sample matrices and validated target proteins. The reason for this adjustment was to ensure sufficient benchmarking data to suport our discussions with future collaboration partners. This strategic choice proved to be right since we will now continue the development through the collaboration with AstraZeneca.